摘要
目前,对丙型肝炎患者的抗病毒治疗均采用直接抗病毒药物(DAAs)。由于DAAs品种较多,为方便临床医师选用,本文推荐择必达或吉利德三代(丙通沙)药物治疗,而G/P鸡尾酒(Maviret)疗法可作为其他DAAs治疗失效患者选用。文中还对这些小分子药物的安全性与耐药率作了介绍,以供参考。
At present,drug therapies for hepatitis C patients are using a large variety of direct-acting antiviral agents(DAAs).In order to facilitate clinicians for selection of appropriate therapeutic agents,the author recommends Zepatier or Gilead third-generation(Epdusa)for treatment,and G/P cocktail(Maviret)therapy for patients with failure of other DAAs treatments.In this article,the author also discusses the safety and resistance rate of these small molecule drugs to provide reference for clinicians.
作者
马亦林
Ma Yilin(Department of Infectious Diseases,State Key Laboratory for Diagnosis and Treatment o f Infectious Diseases,National Clinical Research Center for Infectious Diseases,The First Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310003,China)
出处
《中华临床感染病杂志》
CSCD
2020年第5期371-374,共4页
Chinese Journal of Clinical Infectious Diseases
关键词
肝炎
丙型
直接抗病毒药物
治疗方案推荐
安全性
Hepatitis C
Direct-acting antiviral agents
Therapy recommendation
Safety
作者简介
马亦林,Email:zjumyl@aliyun.com。
